Eyebiotech Ltd.
Clinical trials sponsored by Eyebiotech Ltd., explained in plain language.
-
New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss
Disease control OngoingThis study tests a new drug called EYE103 (Restoret) against an existing treatment, ranibizumab (Lucentis), for people with diabetic macular edema, a condition that causes vision loss in diabetes. About 984 participants will receive injections into the eye every 4 weeks for a yea…
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New eye drug EYE103 takes on standard treatment for Diabetes-Related vision loss
Disease control OngoingThis study tests a new drug called EYE103 (Restoret) against an existing treatment, ranibizumab (Lucentis), for people with diabetic macular edema, a common cause of vision loss in diabetes. About 1,054 participants receive injections into the eye every 4 weeks for a year, then l…
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New eye injection shows promise for blinding swelling
Disease control OngoingThis early-stage study tests a new drug called EYE201, given as three eye injections over 12 weeks, to see if it is safe and can help reduce swelling in the back of the eye. It includes people with three different eye conditions that cause vision loss: branch retinal vein occlusi…
Phase: PHASE1, PHASE2 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC